乳腺癌的新兴疗法。
Emerging therapies for breast cancer.
作者信息
Hu Xichun, Huang Wei, Fan Minhao
机构信息
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
出版信息
J Hematol Oncol. 2017 Apr 28;10(1):98. doi: 10.1186/s13045-017-0466-3.
Abstract
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
摘要
人表皮生长因子受体2（HER2）和细胞周期蛋白依赖性激酶4/6（CDK4/6）无疑是乳腺癌最重要的两个生物学靶点。抗HER2治疗可提高客观缓解率、无进展生存期/无病生存期以及总生存期。三种CDK4/6抑制剂均持续改善客观缓解率和无进展生存期；然而，总生存期数据仍有待观察。化疗和内分泌治疗策略的优化仍是未满足的需求。基于检查点抑制剂的免疫疗法联合化疗是一个有前景的领域，尤其是对于三阴性乳腺癌。
相似文献
1
Emerging therapies for breast cancer.乳腺癌的新兴疗法。
J Hematol Oncol. 2017 Apr 28;10(1):98. doi: 10.1186/s13045-017-0466-3.
2
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.帕博西尼联合氟维司群治疗绝经前激素受体阳性晚期乳腺癌患者的效果：PALOMA-3 研究结果
Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26.
3
Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.CDK4/6 抑制剂联合内分泌治疗在 HR 阳性/HER2-阴性和 HER2 低表达阳性转移性乳腺癌中的临床疗效：PALOMA-2 和 PALOMA-3 试验的二次分析。
EBioMedicine. 2024 Jul;105:105186. doi: 10.1016/j.ebiom.2024.105186. Epub 2024 Jun 10.
4
Recent advances of highly selective CDK4/6 inhibitors in breast cancer.高选择性CDK4/6抑制剂在乳腺癌治疗中的最新进展
J Hematol Oncol. 2017 Apr 24;10(1):97. doi: 10.1186/s13045-017-0467-2.
5
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.CDK4/6 和 PI3K 抑制剂：HER2 阳性乳腺癌患者的新希望。
Eur J Clin Invest. 2021 Jul;51(7):e13535. doi: 10.1111/eci.13535. Epub 2021 Mar 16.
6
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.FDA 批准帕博西尼联合氟维司群用于治疗激素受体阳性、HER2 阴性转移性乳腺癌。
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972. doi: 10.1158/1078-0432.CCR-16-0493. Epub 2016 Jul 12.
7
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.绝经后激素受体阳性、HER2 阴性转移性乳腺癌患者的内分泌治疗与化疗：系统评价和网络荟萃分析。
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
8
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.帕博西尼治疗激素受体阳性晚期乳腺癌。
N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.
9
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.SERD/SERM 杂交 CDK4/6 抑制剂组合在内分泌治疗抵抗性乳腺癌模型中的疗效
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.
10
Palbociclib Extends Survival in Advanced Breast Cancer.帕博西尼延长晚期乳腺癌患者生存期。
Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2.
引用本文的文献
1
Integrating scRNA-seq and spatial transcriptomics to explore the implication of G6PD on immune microenvironment in lymphatic metastasis of breast cancer.整合单细胞RNA测序和空间转录组学以探究葡萄糖-6-磷酸脱氢酶（G6PD）在乳腺癌淋巴转移中对免疫微环境的影响。
Med Oncol. 2025 Jul 21;42(8):355. doi: 10.1007/s12032-025-02943-7.
2
Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.乳腺癌中PI3K/AKT/mTOR通路独特的mRNA表达谱及miRNA调控因子：对肿瘤进展和治疗靶点的见解
Front Oncol. 2025 Jan 9;14:1515387. doi: 10.3389/fonc.2024.1515387. eCollection 2024.
3
Mechanisms of endocrine resistance in hormone receptor-positive breast cancer.激素受体阳性乳腺癌内分泌抵抗的机制
Front Oncol. 2024 Oct 31;14:1448687. doi: 10.3389/fonc.2024.1448687. eCollection 2024.
4
Recent advances in the strategic incorporation of fluorine into new-generation taxoid anticancer agents.氟在新一代紫杉烷类抗癌药物中的策略性引入的最新进展。
J Fluor Chem. 2023 Apr;267. doi: 10.1016/j.jfluchem.2023.110106. Epub 2023 Feb 21.
5
A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022.2003年至2022年乳腺癌靶向治疗研究趋势与热点的文献计量学及可视化分析
Front Oncol. 2024 Jun 4;14:1366900. doi: 10.3389/fonc.2024.1366900. eCollection 2024.
6
Circulating tumor DNA: from discovery to clinical application in breast cancer.循环肿瘤 DNA：从发现到在乳腺癌中的临床应用。
Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024.
7
Exploring Phytochemicals as Potential Inhibitors for Breast Cancer Genes BRCA1 and BRCA2 Using Pharmacophore Modeling, Molecular Docking, MD Simulations, and DFT Analysis.利用药效团模型、分子对接、分子动力学模拟和密度泛函理论分析探索植物化学物质作为乳腺癌基因BRCA1和BRCA2的潜在抑制剂
ACS Omega. 2024 Jan 3;9(2):2161-2182. doi: 10.1021/acsomega.3c05098. eCollection 2024 Jan 16.
8
Cell-cell communication characteristics in breast cancer metastasis.乳腺癌转移中的细胞间通讯特征。
Cell Commun Signal. 2024 Jan 19;22(1):55. doi: 10.1186/s12964-023-01418-4.
9
Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer.锌指蛋白382拮抗乳腺癌中的细胞周期蛋白依赖性激酶25A（CDC25A）和锌指E盒结合蛋白1（ZEB1）信号通路。
Genes Dis. 2022 Feb 9;10(2):568-582. doi: 10.1016/j.gendis.2021.12.019. eCollection 2023 Mar.
10
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的嵌合抗原受体T细胞疗法进展
J Clin Med. 2023 Mar 10;12(6):2173. doi: 10.3390/jcm12062173.
本文引用的文献
1
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.白蛋白结合型紫杉醇联合卡铂或吉西他滨对比吉西他滨联合卡铂作为三阴性转移性乳腺癌一线治疗的患者：tnAcity 试验的结果。
Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.
2
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.比较 ERBB2/HER2 阴性乳腺癌女性患者新辅助 Nab-紫杉醇与紫杉醇联合蒽环类药物治疗的疗效-新辅助 ABI 紫杉醇（ETNA）试验的疗效评估：一项随机 3 期临床试验。
JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.
3
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline mutation demonstrates marked activity.针对携带种系突变的可手术乳腺癌患者的新辅助他拉唑帕利可行性研究显示出显著活性。
NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.
4
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.avelumab，一种抗 PD-L1 抗体，用于局部晚期或转移性乳腺癌患者：JAVELIN 固体肿瘤研究 1b 期。
Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.
5
-Paclitaxel for the treatment of breast cancer: an update across treatment settings.紫杉醇用于治疗乳腺癌：各治疗场景的最新进展
Exp Hematol Oncol. 2017 Mar 22;6:7. doi: 10.1186/s40164-017-0066-5. eCollection 2017.
6
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors.一项在携带胚系突变的卵巢癌或其他实体瘤患者中开展的口服 PARP 抑制剂鲁卡帕利的 I/II 期研究。
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
7
New development in CAR-T cell therapy.嵌合抗原受体T细胞疗法的新进展。
J Hematol Oncol. 2017 Feb 21;10(1):53. doi: 10.1186/s13045-017-0423-1.
8
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.乌地昔单抗联合卡培他滨对比卡培他滨单药治疗蒽环类和紫杉类耐药的转移性乳腺癌：一项多中心、开放标签、优效性、3 期、随机对照临床试验。
Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11.
9
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.帕博利珠单抗治疗局部晚期或转移性尿路上皮癌患者的安全性和活性（KEYNOTE-012）：一项非随机、开放标签、Ib 期研究。
Lancet Oncol. 2017 Feb;18(2):212-220. doi: 10.1016/S1470-2045(17)30007-4. Epub 2017 Jan 10.
10
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.曲妥珠单抗恩美曲妥珠单抗联合或不联合帕妥珠单抗对比曲妥珠单抗联合紫杉烷用于人表皮生长因子受体2阳性晚期乳腺癌：III期MARIANNE研究的主要结果
J Clin Oncol. 2017 Jan 10;35(2):141-148. doi: 10.1200/JCO.2016.67.4887. Epub 2016 Nov 7.
Zotero 插件